These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38301413)

  • 1. Peptide nanovaccine in melanoma immunotherapy.
    Dehghankhold M; Sadat Abolmaali S; Nezafat N; Mohammad Tamaddon A
    Int Immunopharmacol; 2024 Mar; 129():111543. PubMed ID: 38301413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy.
    Yip T; Qi X; Yan H; Chang Y
    ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanovaccines: An effective therapeutic approach for cancer therapy.
    Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH
    Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymph node-targeting nanovaccines for cancer immunotherapy.
    Wang Q; Wang Z; Sun X; Jiang Q; Sun B; He Z; Zhang S; Luo C; Sun J
    J Control Release; 2022 Nov; 351():102-122. PubMed ID: 36115556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen.
    Hashemi Goradel N; Nemati M; Bakhshandeh A; Arashkia A; Negahdari B
    Int Immunopharmacol; 2023 Apr; 117():109887. PubMed ID: 36841155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Self-adjuvanting cancer nanovaccines.
    Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K
    J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymph node-targeted neoantigen nanovaccines potentiate anti-tumor immune responses of post-surgical melanoma.
    Chu Y; Qian L; Ke Y; Feng X; Chen X; Liu F; Yu L; Zhang L; Tao Y; Xu R; Wei J; Liu B; Liu Q
    J Nanobiotechnology; 2022 Apr; 20(1):190. PubMed ID: 35418151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythrocyte Membrane-Enveloped Polymeric Nanoparticles as Nanovaccine for Induction of Antitumor Immunity against Melanoma.
    Guo Y; Wang D; Song Q; Wu T; Zhuang X; Bao Y; Kong M; Qi Y; Tan S; Zhang Z
    ACS Nano; 2015 Jul; 9(7):6918-33. PubMed ID: 26153897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy and Prevention of Cancer by Nanovaccines Loaded with Whole-Cell Components of Tumor Tissues or Cells.
    Ma L; Diao L; Peng Z; Jia Y; Xie H; Li B; Ma J; Zhang M; Cheng L; Ding D; Zhang X; Chen H; Mo F; Jiang H; Xu G; Meng F; Zhong Z; Liu M
    Adv Mater; 2021 Oct; 33(43):e2104849. PubMed ID: 34536044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections.
    Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y
    Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Cancer Nanovaccines: Harnessing Nanotechnology for Broadening Cancer Immune Response.
    Wang QT; Liu YX; Wang J; Wang H
    ChemMedChem; 2023 Jul; 18(13):e202200673. PubMed ID: 37088719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach.
    Kakwere H; Ingham ES; Allen R; Mahakian LM; Tam SM; Zhang H; Silvestrini MT; Lewis JS; Ferrara KW
    Bioconjug Chem; 2017 Nov; 28(11):2756-2771. PubMed ID: 28956907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.
    Li Y; Li S; Jiang Z; Tan K; Meng Y; Zhang D; Ma X
    J Nanobiotechnology; 2023 Jul; 21(1):212. PubMed ID: 37415161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy.
    Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W
    Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide Vaccines in Melanoma: Chemical Approaches towards Improved Immunotherapeutic Efficacy.
    Biri-Kovács B; Bánóczi Z; Tummalapally A; Szabó I
    Pharmaceutics; 2023 Jan; 15(2):. PubMed ID: 36839774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Application of biomimetic nanovaccines in cancer immunotherapy: A useful strategy to help combat immunotherapy resistance.
    Xu Z; Zhou H; Li T; Yi Q; Thakur A; Zhang K; Ma X; Qin JJ; Yan Y
    Drug Resist Updat; 2024 Jul; 75():101098. PubMed ID: 38833804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy.
    Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X
    Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Nanovaccines: Nanomaterials and Clinical Perspectives.
    Desai N; Chavda V; Singh TRR; Thorat ND; Vora LK
    Small; 2024 Aug; 20(35):e2401631. PubMed ID: 38693099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid-enveloped zinc phosphate hybrid nanoparticles for codelivery of H-2K(b) and H-2D(b)-restricted antigenic peptides and monophosphoryl lipid A to induce antitumor immunity against melanoma.
    Zhuang X; Wu T; Zhao Y; Hu X; Bao Y; Guo Y; Song Q; Li G; Tan S; Zhang Z
    J Control Release; 2016 Apr; 228():26-37. PubMed ID: 26921522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response.
    Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.